Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
"We will respond as appropriate to the issues raised by the examiner, and believe we have compelling arguments in our favor," said Pfizer General Counsel Allen Waxman. "We continue to believe that the basic patent was properly granted and will be upheld on reexamination. This initial action, which was not unexpected, does not change that."
The patent remains valid and enforceable throughout the re-examination proceeding, which could take as long as a few years.
More information can be found at www.pfizer.com.
Chris Loder, 212-733-7897
Suzanne Harnett, 212-733-8009
Posted: January 2008